Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice

M Ząbczyk, RAS Ariëns, A Undas - Cardiovascular research, 2023 - academic.oup.com
Fibrinogen conversion into insoluble fibrin and the formation of a stable clot is the final step
of the coagulation cascade. Fibrin clot porosity and its susceptibility to plasmin-mediated …

Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases

L Recinella, G Orlando, C Ferrante… - Frontiers in …, 2020 - frontiersin.org
Besides its role as an energy storage organ, adipose tissue can be viewed as a dynamic
and complex endocrine organ, which produces and secretes several adipokines, including …

A genomic mutational constraint map using variation in 76,156 human genomes

S Chen, LC Francioli, JK Goodrich, RL Collins, M Kanai… - Nature, 2024 - nature.com
The depletion of disruptive variation caused by purifying natural selection (constraint) has
been widely used to investigate protein-coding genes underlying human disorders,,–, but …

A genome-wide mutational constraint map quantified from variation in 76,156 human genomes

S Chen, LC Francioli, JK Goodrich, RL Collins, M Kanai… - BioRxiv, 2022 - biorxiv.org
The depletion of disruptive variation caused by purifying natural selection (constraint) has
been widely used to investigate protein-coding genes underlying human disorders, but …

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022

T Okamura, K Tsukamoto, H Arai, Y Fujioka… - … of atherosclerosis and …, 2024 - jstage.jst.go.jp
In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

A narrative review on plasminogen activator inhibitor-1 and its (patho) physiological role: to target or not to target?

M Sillen, PJ Declerck - International journal of molecular sciences, 2021 - mdpi.com
Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen
activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system …

Lipoprotein (a)—the crossroads of atherosclerosis, atherothrombosis and inflammation

S Ugovšek, M Šebeštjen - Biomolecules, 2021 - mdpi.com
Increased lipoprotein (a)(Lp (a)) levels are an independent predictor of coronary artery
disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD …

Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition

M Sillen, PJ Declerck - Frontiers in Cardiovascular Medicine, 2020 - frontiersin.org
Plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin)
superfamily with antiprotease activity, is the main physiological inhibitor of tissue-type (tPA) …

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

GA Figtree, ST Vernon, JA Harmer, MP Gray… - Journal of the American …, 2023 - jacc.org
Reducing the incidence and prevalence of standard modifiable cardiovascular risk factors
(SMuRFs) is critical to tackling the global burden of coronary artery disease (CAD) …

[HTML][HTML] Cardiovascular biomarkers: lessons of the past and prospects for the future

F Omran, I Kyrou, F Osman, VG Lim… - International Journal of …, 2022 - mdpi.com
Cardiovascular diseases (CVDs) are a major healthcare burden on the population
worldwide. Early detection of this disease is important in prevention and treatment to …